{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:07:44Z","timestamp":1777961264471,"version":"3.51.4"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s11912-018-0706-x","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T07:40:26Z","timestamp":1528270826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Utility of Liquid Biopsy in Central Nervous System Malignancies"],"prefix":"10.1007","volume":"20","author":[{"given":"Kathryn S.","family":"Nevel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Wilcox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsay J.","family":"Robell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshie","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"706_CR1","unstructured":"Lonjaret L et al.. Postoperative complications after craniotomy for brain tumor surgery. Anaesth Crit Care Pain Med, 2016."},{"issue":"5","key":"706_CR2","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1227\/NEU.0b013e31820c0441","volume":"68","author":"B Lassen","year":"2011","unstructured":"Lassen B, Helseth E, R\u00f8nning P, Scheie D, Johannesen TB, M\u00e6hlen J, et al. Surgical mortality at 30 days and complications leading to recraniotomy in 2630 consecutive craniotomies for intracranial tumors. Neurosurgery. 2011;68(5):1259\u201368. discussion 1268\u20139","journal-title":"Neurosurgery"},{"issue":"3","key":"706_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1001\/archneur.1986.00520030059015","volume":"43","author":"A Twijnstra","year":"1986","unstructured":"Twijnstra A, Nooyen WJ, van Zanten AP, Hart AAM, de Visser BWO. Cerebrospinal fluid carcinoembryonic antigen in patients with metastatic and nonmetastatic neurological diseases. Arch Neurol. 1986;43(3):269\u201372.","journal-title":"Arch Neurol"},{"issue":"11","key":"706_CR4","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1136\/jnnp.49.11.1246","volume":"49","author":"A Twijnstra","year":"1986","unstructured":"Twijnstra A, van Zanten AP, Nooyen WJ, Ongerboer de Visser BW. Sensitivity and specificity of single and combined tumour markers in the diagnosis of leptomeningeal metastasis from breast cancer. J Neurol Neurosurg Psychiatry. 1986;49(11):1246\u201350.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"706_CR5","first-page":"2467870","volume":"2017","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Tian C, Shi Q, Hao J, Zhao N, Liu Z. Diagnostic value of CYFRA 21-1 in the cerebrospinal fluid for leptomeningeal metastasis. Dis Markers. 2017;2017:2467870.","journal-title":"Dis Markers"},{"issue":"5","key":"706_CR6","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S1470-2045(08)70125-6","volume":"9","author":"D Brandsma","year":"2008","unstructured":"Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9(5):453\u201361.","journal-title":"Lancet Oncol"},{"issue":"3","key":"706_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1158\/2326-6066.CIR-15-0160","volume":"4","author":"JV Cohen","year":"2016","unstructured":"Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, Goldberg SB, Mahajan A, et al. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. Cancer Immunol Res. 2016;4(3):179\u201382.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"706_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947\u201357.","journal-title":"N Engl J Med"},{"issue":"8","key":"706_CR9","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735\u201342.","journal-title":"Lancet Oncol"},{"key":"706_CR10","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature17038","volume":"529","author":"J Massagu\u00e9","year":"2016","unstructured":"Massagu\u00e9 J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298\u2013306.","journal-title":"Nature"},{"key":"706_CR11","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/1758834010378414","volume":"2","author":"MG Krebs","year":"2010","unstructured":"Krebs MG, Hou JM, Ward TH, Blackhall FH, Dive C. Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol. 2010;2:351\u201365.","journal-title":"Ther Adv Med Oncol"},{"key":"706_CR12","doi-asserted-by":"publisher","first-page":"5663","DOI":"10.1007\/s13277-016-4796-5","volume":"37","author":"Y Hong","year":"2016","unstructured":"Hong Y, Zhang Q. Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks. Tumor Biol. 2016;37:5663\u201374.","journal-title":"Tumor Biol"},{"key":"706_CR13","first-page":"146","volume":"14","author":"TR Ashworth","year":"1869","unstructured":"Ashworth TR. A case of cancer in which cells similar to the tumours were seen in the blood after death. Med J Aust. 1869;14:146\u20137.","journal-title":"Med J Aust"},{"issue":"25","key":"706_CR14","doi-asserted-by":"publisher","first-page":"25ra23","DOI":"10.1126\/scitranslmed.3000403","volume":"2","author":"SL Stott","year":"2010","unstructured":"Stott SL, Lee RJ, Nagrath S, Yu M, Miyamoto DT, Ulkus L, et al. Isolation and characterization of circulating tumor cells from localized and metastatic prostate cancer patients. Sci Transl Med. 2010;2(25):25ra23.","journal-title":"Sci Transl Med"},{"issue":"8","key":"706_CR15","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1073\/pnas.95.8.4589","volume":"95","author":"E Racila","year":"1998","unstructured":"Racila E, Euhus D, Weiss AJ, Rao C, McConnell J, Terstappen LWMM, et al. Detection and characterization of carcinoma cells in the blood. Proc Natl Acad Sci U S A. 1998;95(8):4589\u201394.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"706_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781\u201391.","journal-title":"N Engl J Med"},{"issue":"1\u20132","key":"706_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-010-0115-3","volume":"11","author":"BP Negin","year":"2010","unstructured":"Negin BP, Cohen SJ. Circulating tumor cells in colorectal cancer: past, present, and future challenges. Curr Treat Options in Oncol. 2010;11(1\u20132):1\u201313.","journal-title":"Curr Treat Options in Oncol"},{"issue":"4","key":"706_CR18","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40291-014-0101-8","volume":"18","author":"G Galletti","year":"2014","unstructured":"Galletti G, Portella L, Tagawa ST, Kirby BJ, Giannakakou P, Nanus DM. Circulating tumor cells in prostate Cancer diagnosis and monitoring: an appraisal of clinical potential. Mol Diagn Ther. 2014;18(4):389\u2013402.","journal-title":"Mol Diagn Ther"},{"issue":"10","key":"706_CR19","doi-asserted-by":"publisher","first-page":"3172","DOI":"10.1172\/JCI38609","volume":"119","author":"T Kojima","year":"2009","unstructured":"Kojima T, Hashimoto Y, Watanabe Y, Kagawa S, Uno F, Kuroda S, et al. A simple biological imaging system for detecting viable human circulating tumor cells. J Clin Invest. 2009;119(10):3172\u201381.","journal-title":"J Clin Invest"},{"key":"706_CR20","doi-asserted-by":"crossref","unstructured":"Nagrath S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2009, 450:1235\u20139.","DOI":"10.1038\/nature06385"},{"issue":"1","key":"706_CR21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1515\/med-2016-0005","volume":"11","author":"M Ning","year":"2016","unstructured":"Ning M, et al. Diagnostic value of circulating tumor cells in cerebrospinal fluid. Open Med (Wards). 2016;11(1):21\u20134.","journal-title":"Open Med (Wards)"},{"issue":"8","key":"706_CR22","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1039\/C6CS00803H","volume":"46","author":"Z Shen","year":"2017","unstructured":"Shen Z, Wu A, Chen X. Current detection technologies for circulating tumor cells. Chem Soc Rev. 2017;46(8):2038\u201356.","journal-title":"Chem Soc Rev"},{"issue":"4","key":"706_CR23","doi-asserted-by":"publisher","first-page":"e0175414","DOI":"10.1371\/journal.pone.0175414","volume":"12","author":"P Balasubramanian","year":"2017","unstructured":"Balasubramanian P, Kinders RJ, Kummar S, Gupta V, Hasegawa D, Menachery A, et al. Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream\u00ae system. PLoS One. 2017;12(4):e0175414.","journal-title":"PLoS One"},{"key":"706_CR24","doi-asserted-by":"publisher","first-page":"43464","DOI":"10.1038\/srep43464","volume":"7","author":"WT Yan","year":"2017","unstructured":"Yan WT, Cui X, Chen Q, Li YF, Cui YH, Wang Y, et al. Circulating tumor cell status monitors the treatment responses in breast cancer patients: a meta-analysis. Sci Rep. 2017;7:43464.","journal-title":"Sci Rep"},{"issue":"19","key":"706_CR25","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1200\/JCO.2007.15.8923","volume":"26","author":"SJ Cohen","year":"2008","unstructured":"Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3212\u201321.","journal-title":"J Clin Oncol"},{"issue":"19","key":"706_CR26","doi-asserted-by":"publisher","first-page":"6302","DOI":"10.1158\/1078-0432.CCR-08-0872","volume":"14","author":"JS Bono de","year":"2008","unstructured":"de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302\u20139.","journal-title":"Clin Cancer Res"},{"issue":"55","key":"706_CR27","doi-asserted-by":"publisher","first-page":"R74","DOI":"10.1186\/bcr1783","volume":"9","author":"T Fehm","year":"2007","unstructured":"Fehm T, Becker S, Duerr-Stoerzer S, Sotlar K, Mueller V, Wallwiener D, et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status. Breast Cancer Res. 2007;9(55):R74.","journal-title":"Breast Cancer Res"},{"key":"706_CR28","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1056\/NEJMoa0800668","volume":"359","author":"S Maheswaran","year":"2008","unstructured":"Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med. 2008;359:366\u201377.","journal-title":"N Engl J Med"},{"issue":"1","key":"706_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s10555-012-9398-0","volume":"32","author":"F-C Bidard","year":"2013","unstructured":"Bidard F-C, Fehm T, Ignatiadis M, Smerage JB, Alix-Panabi\u00e8res C, Janni W, et al. Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. Cancer Metastasis Rev. 2013;32(1):179\u201388.","journal-title":"Cancer Metastasis Rev"},{"issue":"10","key":"706_CR30","doi-asserted-by":"publisher","first-page":"752","DOI":"10.18632\/oncotarget.336","volume":"2","author":"AS Patel","year":"2011","unstructured":"Patel AS, Allen JE, Dicker DT, Peters KL, Sheehan JM, Glantz MJ, et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases. Oncotarget. 2011;2(10):752\u201360.","journal-title":"Oncotarget"},{"issue":"17","key":"706_CR31","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1212\/WNL.0b013e31828f183f","volume":"80","author":"L Nayak","year":"2013","unstructured":"Nayak L, Fleisher M, Gonzalez-Espinoza R, Lin O, Panageas K, Reiner A, et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology. 2013;80(17):1598\u2013605. discussion 1603","journal-title":"Neurology"},{"issue":"2","key":"706_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10549-015-3610-1","volume":"154","author":"JS Lee","year":"2015","unstructured":"Lee JS, Melisko ME, Magbanua MJM, Kablanian AT, Scott JH, Rugo HS, et al. Detection of cerebrospinal fluid tumor cells and its clinical relevance in leptomeningeal metastasis of breast cancer. Breast Cancer Res Treat. 2015;154(2):339\u201349.","journal-title":"Breast Cancer Res Treat"},{"issue":"9","key":"706_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1093\/neuonc\/nox066","volume":"19","author":"X Lin","year":"2017","unstructured":"\u2022 Lin X, et al. Cerebrospinal fluid circulating tumor cells: a novel tool to diagnose leptomeningeal metastases from epithelial tumors. Neuro-Oncology. 2017;19(9):1248\u201354. This paper revealed the high sensitivity and specificity of CSF circulating tumor cell detection to diagnose leptomeningeal metastasis from solid tumor malignancies of epithelial cell origin.","journal-title":"Neuro-Oncology"},{"key":"706_CR34","doi-asserted-by":"crossref","unstructured":"Malani R et al.. Cerebrospinal fluid circulating tumor cells (CSF CTC) for real-time patient monitoring and response to treatment. J Clin Oncol, 2017. 35: p. suppl; abstr 11549.","DOI":"10.1200\/JCO.2017.35.15_suppl.11549"},{"issue":"1\u20132","key":"706_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.cellimm.2014.08.002","volume":"292","author":"S Tug","year":"2014","unstructured":"Tug S, Helmig S, Menke J, Zahn D, Kubiak T, Schwarting A, et al. Correlation between cell free DNA levels and medical evaluation of disease progression in systemic lupus erythematosus patients. Cell Immunol. 2014;292(1\u20132):32\u20139.","journal-title":"Cell Immunol"},{"issue":"10","key":"706_CR36","doi-asserted-by":"publisher","first-page":"e25969","DOI":"10.1371\/journal.pone.0025969","volume":"6","author":"TT Ha","year":"2011","unstructured":"Ha TT, et al. Elevated levels of cell-free circulating DNA in patients with acute dengue virus infection. PLoS One. 2011;6(10):e25969.","journal-title":"PLoS One"},{"issue":"2","key":"706_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.canlet.2016.02.002","volume":"374","author":"A Szpechcinski","year":"2016","unstructured":"Szpechcinski A, Rudzinski P, Kupis W, Langfort R, Orlowski T, Chorostowska-Wynimko J. Plasma cell-free DNA levels and integrity in patients with chest radiological findings: NSCLC versus benign lung nodules. Cancer Lett. 2016;374(2):202\u20137.","journal-title":"Cancer Lett"},{"issue":"28","key":"706_CR38","doi-asserted-by":"publisher","first-page":"44583","DOI":"10.18632\/oncotarget.10069","volume":"7","author":"B Ai","year":"2016","unstructured":"Ai B, Liu H, Huang Y, Peng P. Circulating cell-free DNA as a prognostic and predictive biomarker in non-small cell lung cancer. Oncotarget. 2016;7(28):44583\u201395.","journal-title":"Oncotarget"},{"issue":"3","key":"706_CR39","first-page":"646","volume":"37","author":"SA Leon","year":"1977","unstructured":"Leon SA, Shapiro B, Sklaroff DM, Yaros MJ. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977;37(3):646\u201350.","journal-title":"Cancer Res"},{"issue":"1","key":"706_CR40","first-page":"67","volume":"3","author":"GD Sorenson","year":"1994","unstructured":"Sorenson GD, et al. Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev. 1994;3(1):67\u201371.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"5","key":"706_CR41","doi-asserted-by":"publisher","first-page":"R71","DOI":"10.1186\/bcr2404","volume":"11","author":"H Schwarzenbach","year":"2009","unstructured":"Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, et al. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res. 2009;11(5):R71.","journal-title":"Breast Cancer Res"},{"key":"706_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1196\/annals.1448.022","volume":"1137","author":"M Vaart van der","year":"2008","unstructured":"van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann N Y Acad Sci. 2008;1137:18\u201326.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"706_CR43","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/nrclinonc.2013.110","volume":"10","author":"E Crowley","year":"2013","unstructured":"Crowley E, di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472\u201384.","journal-title":"Nat Rev Clin Oncol"},{"issue":"9","key":"706_CR44","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985\u201390.","journal-title":"Nat Med"},{"issue":"20","key":"706_CR45","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1200\/JCO.2016.66.6487","volume":"34","author":"EI Pentsova","year":"2016","unstructured":"\u2022 Pentsova EI, et al. Evaluating cancer of the central nervous system through next-generation sequencing of cerebrospinal fluid. J Clin Oncol. 2016;34(20):2404\u201315. This study demonstrated that ctDNA in the CSF can be analyzed to assess for clinically relevant genomic alterations in patients with CNS cancers. ctDNA in the CSF can reveal clinically important mutations that help guide treatment decisions, and show early mechanisms of drug resistance.","journal-title":"J Clin Oncol"},{"issue":"31","key":"706_CR46","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1073\/pnas.1511694112","volume":"112","author":"Y Wang","year":"2015","unstructured":"\u2022 Wang Y, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112(31):9704\u20139. This study showed that CSF ctDNA can be used in lieu of a tissue biopsy in surgically high-risk patients. It also importantly showed that CSF ctDNA is of highest yield in patients with tumors that abut the ventricle.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"706_CR47","doi-asserted-by":"publisher","first-page":"8817","DOI":"10.1073\/pnas.1133470100","volume":"100","author":"D Dressman","year":"2003","unstructured":"Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100(15):8817\u201322.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"706_CR48","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/nmeth898","volume":"3","author":"F Diehl","year":"2006","unstructured":"Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3(7):551\u20139.","journal-title":"Nat Methods"},{"key":"706_CR49","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1038\/mtna.2013.28","volume":"2","author":"WW Chen","year":"2013","unstructured":"Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2:e109.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"706_CR50","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J, Wynne JF, Eclov NCW, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548\u201354.","journal-title":"Nat Med"},{"key":"706_CR51","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.2147\/OTT.S99807","volume":"9","author":"S Serrati","year":"2016","unstructured":"Serrati S, et al. Next-generation sequencing: advances and applications in cancer diagnosis. Onco Targets Ther. 2016;9:7355\u201365.","journal-title":"Onco Targets Ther"},{"issue":"5","key":"706_CR52","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s13402-014-0196-2","volume":"37","author":"D Sie","year":"2014","unstructured":"Sie D, Snijders PJF, Meijer GA, Doeleman MW, van Moorsel MIH, van Essen HF, et al. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology. Cell Oncol (Dordr). 2014;37(5):353\u201361.","journal-title":"Cell Oncol (Dordr)"},{"issue":"224","key":"706_CR53","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24.","journal-title":"Sci Transl Med"},{"issue":"8","key":"706_CR54","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.15252\/emmm.201404913","volume":"7","author":"E Olsson","year":"2015","unstructured":"Olsson E, Winter C, George A, Chen Y, Howlin J, Tang MHE, et al. Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med. 2015;7(8):1034\u201347.","journal-title":"EMBO Mol Med"},{"issue":"302","key":"706_CR55","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas I, Schiavon G, Weigelt B, Ng C, Hrebien S, Cutts RJ, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.","journal-title":"Sci Transl Med"},{"issue":"346","key":"706_CR56","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.","journal-title":"Sci Transl Med"},{"issue":"3","key":"706_CR57","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.lungcan.2012.11.016","volume":"79","author":"AD Nygaard","year":"2013","unstructured":"Nygaard AD, Garm Spindler KL, Pallisgaard N, Andersen RF, Jakobsen A. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. Lung Cancer. 2013;79(3):312\u20137.","journal-title":"Lung Cancer"},{"issue":"12","key":"706_CR58","doi-asserted-by":"publisher","first-page":"e1002198","DOI":"10.1371\/journal.pmed.1002198","volume":"13","author":"CA Parkinson","year":"2016","unstructured":"Parkinson CA, Gale D, Piskorz AM, Biggs H, Hodgkin C, Addley H, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198.","journal-title":"PLoS Med"},{"key":"706_CR59","doi-asserted-by":"publisher","first-page":"11815","DOI":"10.1038\/ncomms11815","volume":"7","author":"JJ Chabon","year":"2016","unstructured":"Chabon JJ, Simmons AD, Lovejoy AF, Esfahani MS, Newman AM, Haringsma HJ, et al. Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun. 2016;7:11815.","journal-title":"Nat Commun"},{"issue":"1","key":"706_CR60","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11060-013-1209-0","volume":"115","author":"MA Salkeni","year":"2013","unstructured":"Salkeni MA, Zarzour A, Ansay TY, McPherson CM, Warnick RE, Rixe O, et al. Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients. J Neuro-Oncol. 2013;115(1):27\u201335.","journal-title":"J Neuro-Oncol"},{"issue":"4","key":"706_CR61","first-page":"1461","volume":"9","author":"C Balana","year":"2003","unstructured":"Balana C, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res. 2003;9(4):1461\u20138.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"706_CR62","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/neuonc\/nop041","volume":"12","author":"I Lavon","year":"2010","unstructured":"Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T. Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro-Oncology. 2010;12(2):173\u201380.","journal-title":"Neuro-Oncology"},{"issue":"3","key":"706_CR63","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s12031-011-9617-0","volume":"46","author":"W Shi","year":"2012","unstructured":"Shi W, Lv C, Qi J, Zhao W, Wu X, Jing R, et al. Prognostic value of free DNA quantification in serum and cerebrospinal fluid in glioma patients. J Mol Neurosci. 2012;46(3):470\u20135.","journal-title":"J Mol Neurosci"},{"key":"706_CR64","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"L Mattos-Arruda De","year":"2015","unstructured":"\u2022 De Mattos-Arruda L, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839. This study showed that CSF ctDNA is more abundant than serum ctDNA in patients with CNS malginancies, and can be used as an adjunct tool to diagnose leptomeningeal metastasis.","journal-title":"Nat Commun"},{"issue":"3","key":"706_CR65","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1373\/clinchem.2014.235457","volume":"61","author":"W Pan","year":"2015","unstructured":"Pan W, Gu W, Nagpal S, Gephart MH, Quake SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61(3):514\u201322.","journal-title":"Clin Chem"},{"issue":"6","key":"706_CR66","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/neuonc\/nop064","volume":"12","author":"BL Liu","year":"2010","unstructured":"Liu BL, Cheng JX, Zhang W, Zhang X, Wang R, Lin H, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro-Oncology. 2010;12(6):540\u20138.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"706_CR67","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1093\/clinchem\/46.1.132","volume":"46","author":"DW Swinkels","year":"2000","unstructured":"Swinkels DW, de Kok JB, Hanselaar A, Lamers K, Boerman RH. Early detection of leptomeningeal metastasis by PCR examination of tumor-derived K-ras DNA in cerebrospinal fluid. Clin Chem. 2000;46(1):132\u20133.","journal-title":"Clin Chem"},{"issue":"7","key":"706_CR68","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1097\/JTO.0b013e318219aaae","volume":"6","author":"M Shingyoji","year":"2011","unstructured":"Shingyoji M, Kageyama H, Sakaida T, Nakajima T, Matsui Y, Itakura M, et al. Detection of epithelial growth factor receptor mutations in cerebrospinal fluid from patients with lung adenocarcinoma suspected of neoplastic meningitis. J Thorac Oncol. 2011;6(7):1215\u201320.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"706_CR69","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jmoldx.2014.04.008","volume":"16","author":"H Yang","year":"2014","unstructured":"Yang H, Cai L, Zhang Y, Tan H, Deng Q, Zhao M, et al. Sensitive detection of EGFR mutations in cerebrospinal fluid from lung adenocarcinoma patients with brain metastases. J Mol Diagn. 2014;16(5):558\u201363.","journal-title":"J Mol Diagn"},{"issue":"1","key":"706_CR70","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.resinv.2015.07.001","volume":"54","author":"S Sasaki","year":"2016","unstructured":"Sasaki S, Yoshioka Y, Ko R, Katsura Y, Namba Y, Shukuya T, et al. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure. Respir Investig. 2016;54(1):14\u20139.","journal-title":"Respir Investig"},{"issue":"5","key":"706_CR71","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/pbc.22925","volume":"56","author":"T Kimoto","year":"2011","unstructured":"Kimoto T, Inoue M, Tokimasa S, Yagyu S, Iehara T, Hosoi H, et al. Detection of MYCN DNA in the cerebrospinal fluid for diagnosing isolated central nervous system relapse in neuroblastoma. Pediatr Blood Cancer. 2011;56(5):865\u20137.","journal-title":"Pediatr Blood Cancer"},{"issue":"51","key":"706_CR72","doi-asserted-by":"publisher","first-page":"85430","DOI":"10.18632\/oncotarget.13397","volume":"7","author":"P Momtaz","year":"2016","unstructured":"Momtaz P, Pentsova E, Abdel-Wahab O, Diamond E, Hyman D, Merghoub T, et al. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget. 2016;7(51):85430\u20136.","journal-title":"Oncotarget"},{"issue":"1","key":"706_CR73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-016-2081-5","volume":"128","author":"Y Li","year":"2016","unstructured":"Li Y, Pan W, Connolly ID, Reddy S, Nagpal S, Quake S, et al. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neuro-Oncol. 2016;128(1):93\u2013100.","journal-title":"J Neuro-Oncol"},{"issue":"7","key":"706_CR74","doi-asserted-by":"publisher","first-page":"14240","DOI":"10.3390\/ijms140714240","volume":"14","author":"B Hannafon","year":"2013","unstructured":"Hannafon B, Ding W-Q. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013;14(7):14240\u201369.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"706_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s11060-015-1912-0","volume":"125","author":"Z Areeb","year":"2015","unstructured":"Areeb Z, Stylli SS, Koldej R, Ritchie DS, Siegal T, Morokoff AP, et al. MicroRNA as potential biomarkers in glioblastoma. J Neuro-Oncol. 2015;125(2):237\u201348.","journal-title":"J Neuro-Oncol"},{"issue":"14","key":"706_CR76","doi-asserted-by":"publisher","first-page":"6029","DOI":"10.1158\/0008-5472.CAN-05-0137","volume":"65","author":"JA Chan","year":"2005","unstructured":"Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029\u201333.","journal-title":"Cancer Res"},{"issue":"3","key":"706_CR77","doi-asserted-by":"publisher","first-page":"e17438","DOI":"10.1371\/journal.pone.0017438","volume":"6","author":"S Srinivasan","year":"2011","unstructured":"Srinivasan S, Patric IRP, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One. 2011;6(3):e17438.","journal-title":"PLoS One"},{"issue":"24","key":"706_CR78","doi-asserted-by":"publisher","first-page":"12908","DOI":"10.18632\/oncotarget.2679","volume":"5","author":"W Yan","year":"2014","unstructured":"Yan W, Li R, Liu Y, Yang P, Wang Z, Zhang C, et al. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis. Oncotarget. 2014;5(24):12908\u201315.","journal-title":"Oncotarget"},{"key":"706_CR79","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/1479-5876-11-10","volume":"11","author":"S Qiu","year":"2013","unstructured":"Qiu S, Lin S, Hu D, Feng Y, Tan Y, Peng Y. Interactions of miR-323\/miR-326\/miR-329 and miR-130a\/miR-155\/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients. J Transl Med. 2013;11:10.","journal-title":"J Transl Med"},{"issue":"4","key":"706_CR80","first-page":"814","volume":"119","author":"W Zhang","year":"2015","unstructured":"Zhang W, et al. Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer Biol Ther. 2015;119(4):814\u201324.","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"706_CR81","doi-asserted-by":"publisher","first-page":"938","DOI":"10.4161\/cbt.28920","volume":"15","author":"Y Berthois","year":"2014","unstructured":"Berthois Y, et al. Differential expression of miR200a-3p and miR21 in grade II-III and grade IV gliomas: evidence that miR200a-3p is regulated by O(6)-methylguanine methyltrans-ferase and promotes temozolomide responsiveness. Cancer Biol Ther. 2014;15(7):938\u201350.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"706_CR82","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.molonc.2014.11.004","volume":"9","author":"J Hayes","year":"2015","unstructured":"Hayes J, Thygesen H, Tumilson C, Droop A, Boissinot M, Hughes TA, et al. Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signture. Mol Oncol. 2015;9(3):704\u201314.","journal-title":"Mol Oncol"},{"issue":"29","key":"706_CR83","doi-asserted-by":"crossref","first-page":"45764","DOI":"10.18632\/oncotarget.9945","volume":"7","author":"M Niyazi","year":"2016","unstructured":"Niyazi M, et al. A 4-miRNA signature predicts the therapeutic outcome of glioblastoma. Oncotarget. 2016;7(29):45764\u201375.","journal-title":"Oncotarget"},{"issue":"10","key":"706_CR84","doi-asserted-by":"publisher","first-page":"e108950","DOI":"10.1371\/journal.pone.0108950","volume":"9","author":"R Barbano","year":"2014","unstructured":"Barbano R, Palumbo O, Pasculli B, Galasso M, Volinia S, D'Angelo V, et al. A miRNA signature for defining aggressive phenotype and prognosis in gliomas. PLoS One. 2014;9(10):e108950.","journal-title":"PLoS One"},{"issue":"16","key":"706_CR85","doi-asserted-by":"publisher","first-page":"4289","DOI":"10.1158\/1078-0432.CCR-10-0207","volume":"16","author":"Y Guan","year":"2010","unstructured":"Guan Y, Mizoguchi M, Yoshimoto K, Hata N, Shono T, Suzuki SO, et al. MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin Cancer Res. 2010;16(16):4289\u201397.","journal-title":"Clin Cancer Res"},{"key":"706_CR86","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11060-015-1784-3","volume":"123","author":"JC Akers","year":"2015","unstructured":"Akers JC, Ramakrishnan V, Kim R, Phillips S, Kaimal V, Mao Y, et al. miRNA contents of cerebrospinal fluid extracellular vesicles in glioblastoma patients. J Neuro-Oncol. 2015;123:205\u201316.","journal-title":"J Neuro-Oncol"},{"key":"706_CR87","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3171\/2015.1.JNS141577","volume":"124","author":"X Yue","year":"2016","unstructured":"Yue X, Lan FM, Hu M, Pan Q, Wang Q, Wang JH. Downregulation of serum microRNA-205 as a potential diagnostic and prognostic biomarker for human glioma. J Neurosurg. 2016;124:122\u20138.","journal-title":"J Neurosurg"},{"key":"706_CR88","doi-asserted-by":"publisher","first-page":"855","DOI":"10.12659\/MSM.897164","volume":"22","author":"Y Xiao","year":"2016","unstructured":"Xiao Y, Zhang L, Song Z, Guo C, Zhu J, Li Z, et al. Potential diagnostic and prognostic value of plasma circulating MicroRNA-182 in human Glioma. Med Sci Monit. 2016;22:855\u201362.","journal-title":"Med Sci Monit"},{"key":"706_CR89","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/ijc.27657","volume":"132","author":"C Yang","year":"2013","unstructured":"Yang C, Wang C, Chen X, Chen S, Zhang Y, Zhi F, et al. Identification of seven serum microRNAs from a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for malignant astrocytomas. Int J Cancer. 2013;132:116\u201327.","journal-title":"Int J Cancer"},{"issue":"3","key":"706_CR90","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/neuonc\/nou169","volume":"17","author":"F Zhi","year":"2015","unstructured":"Zhi F, Shao N, Wang R, Deng D, Xue L, Wang Q, et al. Identification of 9 serum microRNAs as potential noninvasive biomarkers of human astrocytoma. Neuro-Oncology. 2015;17(3):383\u201391.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"706_CR91","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12943-017-0628-5","volume":"16","author":"H Zhao","year":"2017","unstructured":"Zhao H, Shen J, Hodges TR, Song R, Fuller GN, Heimberger AB. Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017;16(1):59.","journal-title":"Mol Cancer"},{"key":"706_CR92","doi-asserted-by":"publisher","first-page":"20829","DOI":"10.18632\/oncotarget.4096","volume":"6","author":"A Drusco","year":"2015","unstructured":"Drusco A, Bottoni A, Lagan\u00e0 A, Acunzo M, Fassan M, Cascione L, et al. A differentially expressed set of microRNAs in cerebro-spinal fluid can diagnose CNS malignancies. Oncotarget. 2015;6:20829\u201339.","journal-title":"Oncotarget"},{"issue":"6","key":"706_CR93","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/neuonc\/nos074","volume":"14","author":"NM Teplyuk","year":"2012","unstructured":"Teplyuk NM, Mollenhauer B, Gabriely G, Giese A, Kim E, Smolsky M, et al. MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-Oncology. 2012;14(6):689\u2013700.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"706_CR94","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/neuonc\/nor169","volume":"14","author":"A Baraniskin","year":"2012","unstructured":"Baraniskin A, Kuhnhenn J, Schlegel U, Maghnouj A, Zollner H, Schmiegel W, et al. Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-Oncology. 2012;14(1):29\u201333.","journal-title":"Neuro-Oncology"},{"issue":"11","key":"706_CR95","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1182\/blood-2010-09-308684","volume":"117","author":"A Baraniskin","year":"2011","unstructured":"Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood. 2011;117(11):3140\u20136.","journal-title":"Blood"},{"issue":"29","key":"706_CR96","doi-asserted-by":"publisher","first-page":"26971","DOI":"10.18632\/oncotarget.4699","volume":"6","author":"R Shi","year":"2015","unstructured":"\u2022 Shi R, Wang PY, Li XY, Chen JX, Li Y, Zhang XZ, et al. Exosomal levels of miRNA-21 from cerebrospinal fluids associated with poor prognosis and tumor recurrence of glioma patients. Oncotarget. 2015;6(29):26971\u201381. This study demonstrated that miRNA-21 is present in significantly higher levels in the CSF of glioblastoma patients compared to brain trauma controls. These levels were associated with tumor grade and negatively correlated with median overall survival.","journal-title":"Oncotarget"},{"issue":"11","key":"706_CR97","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","volume":"5","author":"PK Brastianos","year":"2015","unstructured":"Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5(11):1164\u201377.","journal-title":"Cancer Discov"},{"issue":"6190","key":"706_CR98","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 2014;344(6190):1396\u2013401.","journal-title":"Science"},{"key":"706_CR99","doi-asserted-by":"publisher","first-page":"22477","DOI":"10.1038\/srep22477","volume":"6","author":"NR Parker","year":"2016","unstructured":"Parker NR, Hudson AL, Khong P, Parkinson JF, Dwight T, Ikin RJ, et al. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Sci Rep. 2016;6:22477.","journal-title":"Sci Rep"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-018-0706-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0706-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-018-0706-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T04:30:11Z","timestamp":1604377811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-018-0706-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":99,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1007\/s11912-018-0706-x","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"assertion":[{"value":"6 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Kathryn S. Nevel, Jessica A. Wilcox, Lindsay J. Robell, and Yoshie Umemura declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"60"}}